1320 Non-clinical characterization of CYT-303 FLEX-NK™ engager antibody supports clinical evaluation

Liang Lin, Vishal Khairnar, Harish Potu, Hao‐Ming Chang, Elisabetta Burchi, Armin Rath, Stanley Frankel, Jean Kadouche, Daniel Teper, Wei Li, Antonio ArulanandamRegular 2022 · DOI

TL;DR

CYT-303 is a novel bispecific "NK cell engager" designed to bridge natural killer (NK) cells to GPC3-positive liver cancer cells. Preclinical studies demonstrate that it successfully triggers multiple immune destruction pathways—including phagocytosis and direct killing—while maintaining a favorable safety and pharmacokinetic profile in non-human primates, supporting its transition into human clinical trials.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC), the most common form of liver cancer, remains a significant clinical challenge with limited treatment options. While immunotherapy has revolutionized oncology, many patients do not respond to standard checkpoint inhibitors.

One promising alternative is the use of Natural Killer (NK) cells, which are potent innate immune effectors. However, getting these cells to specifically recognize and stay engaged with tumor cells is difficult. This paper evaluates CYT-303, a bispecific antibody built on the "FLEX-NK™" platform. It acts as a molecular matchmaker: one arm binds to NKp46 (an activating receptor on NK cells) and the other binds to Glypican-3 (GPC3) (a protein highly expressed on HCC cells). The goal is to prove that this molecule can effectively recruit the immune system to destroy liver cancer while remaining safe for systemic administration.

Methods

The researchers utilized a variety of in vitro and in vivo techniques to characterize CYT-303:

  • FLEX-NK™ Platform: A proprietary design using a "FLEX-linker" and a human IgG1 backbone. This structure allows the antibody to bind simultaneously to the cancer cell and the NK cell while retaining "Fc effector functions" (the ability of the antibody's tail to recruit other immune components).
  • Effector Function Assays: They tested ADCP (Antibody-Dependent Cellular Phagocytosis) using human macrophages and CDC (Complement-Dependent Cytotoxicity) using rabbit complement to see if the antibody could trigger these secondary "cleanup" mechanisms.
  • 3D Tumor Models: Instead of simple flat cell cultures, they used Hep3B tumor spheroids (3D clusters of cancer cells) to better mimic the physical structure of a tumor.
  • Serial Killing Assays: To test the "stamina" of the immune response, they repeatedly added the same NK cells to fresh batches of tumor cells to see if CYT-303 could sustain killing over time.
  • Primate Safety/PK: They conducted single-dose and 4-week repeat-dose studies in cynomolgus monkeys (doses up to 60 mg/kg) to evaluate pharmacokinetics (PK) and potential toxicity.

Datasets

As a preclinical biological study, the "datasets" consist of specific cell lines and animal models:

  • Hep3B: A standard human hepatocellular carcinoma cell line used for the tumor models.
  • Primary Human Cells: Peripheral blood NK cells (PBNKs) and monocytes (differentiated into macrophages) from human donors.
  • Non-Human Primates: Cynomolgus monkeys were used for the safety and pharmacokinetic evaluation.

Key Insights and Ideas

  • Multi-Pronged Attack: CYT-303 doesn't just "tether" NK cells to tumors. Because it uses a human IgG1 backbone, it also recruits macrophages (via ADCP) and the complement system (via CDC). This creates a redundant, more robust anti-tumor response.
  • Sustained Engagement: The serial killing assays are particularly interesting. They suggest that CYT-303 helps NK cells remain active across multiple rounds of tumor encounters, rather than becoming exhausted after the first kill.
  • Safety "Sweet Spot": One of the biggest risks with immune engagers is a "cytokine storm" (over-activation of the immune system). The primate studies showed no evidence of cytokine release or related toxicities even at high doses (60 mg/kg), which is a major green flag for clinical safety.
  • Dose Proportionality: The drug's concentration in the blood (Cmax and AUC) increased linearly with the dose, making its behavior predictable for future human dosing.

Key Results

  • Potency: Maximal ADCP and CDC activity against Hep3B tumors was achieved at relatively low concentrations (0.4 to 2 µg/ml).
  • Killing Kinetics: In 3D spheroid models, NK cell killing peaked at 2–3 days and was significantly enhanced by the presence of CYT-303 in a dose-dependent manner.
  • Pharmacokinetics: In monkeys, the half-life ($T_{1/2}$) ranged from 39 to 47.6 hours, with drug exposure persisting for up to a week after a single dose.
  • Toxicology: No CYT-303-related toxicities were observed in the 4-week repeat-dose study, supporting its safety profile for clinical development.

Limitations and Future Work

The authors note that these results "support CYT-303 clinical development," but several questions remain:

  • In Vivo Efficacy: While safety was proven in primates, the abstract does not detail in vivo tumor shrinkage (efficacy) in animal models (e.g., humanized mice), which is usually the next step.
  • Human Translation: Primate PK and safety don't always translate perfectly to humans, especially regarding the specific affinity for human GPC3 vs. primate GPC3.
  • Clinical Trials: The logical next step—and the ultimate goal of this paper—is the initiation of Phase 1 clinical trials to determine the Recommended Phase 2 Dose (RP2D) and observe initial anti-tumor activity in HCC patients.

Summary updated

Abstract

<h3>Background</h3> CYT-303 is a multifunctional bispecific NK engager (NKE) targeting NK cell activating receptor NKp46 and tumor antigen Glypican-3 (GPC3) expressed in HCC (hepatocellular carcinoma). Cytovia’s proprietary FLEX-NK<sup>TM</sup> platform utilizes a novel FLEX-linker and human IgG1 back bone to allow for simultaneous binding to targeted cancer cells and NK cells. We evaluated additional CYT-303 Fc effector functions and the impact of CYT-303 when added to peripheral blood NK cells (PBNK) in Hep3B tumor spheroid cytolysis and Hep3B tumor serial killing assays. CYT-303 pharmacokinetics and safety in non-human primates were also evaluated. <h3>Methods</h3> CYT-303 Fc effector function against Hep3B tumors was evaluated for antibody dependent cellular phagocytosis (ADCP) using human macrophages differentiated from purified monocytes isolated from peripheral blood and for complement dependent cytotoxicity (CDC) in the presence of rabbit complement. Hep3B tumor spheroids were established in special U-bottom adhesive plates and tumor spheroid killing assays were conducted with PBNKs and CYT-303 using the Incucyte <sup>TM</sup> Live Cell Analysis System. Serial killing assays were conducted by repeatedly adding the same PBNK cells to fresh tumor cells and CYT-303 following each round of tumor killing. CYT-303 single dose range finding pharmacokinetics and safety and 4-week repeat dose safety studies were conducted in cynomolgus monkeys by intravenous infusion dosing at 6, 20 and 60 mg/kg doses. <h3>Results</h3> CYT-303 showed dose dependent ADCP by human macrophages against Hep3B tumors that was maximal at 0.4 ug/ml. CYT-303 also showed maximal CDC against Hep3B tumors at 0.4 – 2 ug/ml concentrations. CYT-303 in the presence of freshly isolated PBNKs showed increased time dependent killing of Hep3B tumor spheroids that peaked at 2-3 days following initiation of killing. This killing was enhanced in the presence of CYT-303 in a dose dependent manner. Furthermore, PBNK serial killing of Hep3B tumors was also enhanced by CYT-303. In the CYT-303 single dose range finding pharmacokinetics study in cynomolgus monkeys the C<sub>max</sub> and AUC<sub>0-168h</sub> values increased with dose and increases were approximately dose-proportional. CYT-303, half-lives (T<sub>1/2</sub>) ranged from 39 to 47.6 hrs and exposures persisted up to 1-week. No evidence for any cytokine release was observed. In the 4-week repeat dose toxicity study no CYT-303 related toxicities were observed, enabling CYT-303 clinical development. <h3>Conclusions</h3> CYT-303 demonstrated potent ADCP and CDC against Hep3B tumors as well as Hep3B tumor spheroid and serial killing activities in the presence of PBNKs. Preclinical pharmacokinetics and safety study results in cynomolgus monkeys support CYT-303 clinical development.
BibTeX
@inproceedings{lin2022non,
  author = {Liang Lin and Vishal Khairnar and Harish Potu and Hao‐Ming Chang and Elisabetta Burchi and Armin Rath and Stanley Frankel and Jean Kadouche and Daniel Teper and Wei Li and Antonio Arulanandam},
  title = {{1320 Non-clinical characterization of CYT-303 FLEX-NK™ engager antibody supports clinical evaluation}},
  booktitle = {Regular},
  year = {2022},
  doi = {10.1136/jitc-2022-sitc2022.1320},
}
Figure